| 27/08/24 | 07:00:07 | 27 Aug 2024 | | ACCRUFeR® Approved by Health Canada |
| 14/08/24 | 07:00:11 | 14 Aug 2024 | | Notice of interim results |
| 24/07/24 | 07:01:01 | 24 Jul 2024 | | Unaudited Q2 2024 Trading Update |
| 24/07/24 | 07:00:10 | 24 Jul 2024 | | Directorate Change |
| 03/07/24 | 07:00:09 | 3 Jul 2024 | | $5.7m Milestone Monetization Agreement with AOP |
| 20/06/24 | 16:25:41 | 20 Jun 2024 | | Results of 2024 Annual General Meeting |
| 28/05/24 | 07:00:17 | 28 May 2024 | | New Drug Application for Accrufer® in South Korea |
| 10/05/24 | 15:30:18 | 10 May 2024 | | Audited results for the year ended 31 Dec 2023 |
| 30/04/24 | 07:00:11 | 30 Apr 2024 | | Business Update for Q1 2024 |
| 16/04/24 | 07:00:13 | 16 Apr 2024 | | Notice of Results |
| 21/02/24 | 07:00:06 | 21 Feb 2024 | | Unaudited Full Year Trading Update |
| 09/01/24 | 07:00:04 | 9 Jan 2024 | | Appointment of new Chief Financial Officer |
| 07/12/23 | 07:00:07 | 7 Dec 2023 | | Q3 2023 U.S. Commercial Highlights |
| 27/11/23 | 17:24:38 | 27 Nov 2023 | | PDMR Transaction Notification |
| 20/10/23 | 11:45:00 | 20 Oct 2023 | | Abstract to be presented at Healthcare Conference |
| 12/10/23 | 07:00:09 | 12 Oct 2023 | | Chief Financial Officer Transition |
| 03/10/23 | 15:00:01 | 3 Oct 2023 | | Result of REX Retail Offer |
| 03/10/23 | 07:00:09 | 3 Oct 2023 | | Block listing Interim Return |
| 03/10/23 | 07:00:06 | 3 Oct 2023 | | Completion of SWK Financing |
| 28/09/23 | 12:50:02 | 28 Sept 2023 | | Successful completion of US$6.1m Equity Fundraise |
| 28/09/23 | 07:02:02 | 28 Sept 2023 | | REX Retail Offer |
| 28/09/23 | 07:01:02 | 28 Sept 2023 | | $20m secured debt facility &proposed equity raise |
| 28/09/23 | 07:00:10 | 28 Sept 2023 | | Interim results update and business update |
| 06/09/23 | 07:00:06 | 6 Sept 2023 | | Notice of Results and Change in reporting currency |
| 24/07/23 | 14:27:13 | 24 Jul 2023 | | Holding(s) in Company |
| 20/07/23 | 07:00:06 | 20 Jul 2023 | | Business Update and U.S. Q2 2023 Highlights |
| 28/06/23 | 17:30:01 | 28 Jun 2023 | | Results of 2023 Annual General Meeting |
| 16/06/23 | 12:00:01 | 16 Jun 2023 | | Form 8.5 (EPT/RI) - Shield Therapeutics Plc |
| 15/06/23 | 16:35:01 | 15 Jun 2023 | | Lapse of Offer |
| 15/06/23 | 12:00:02 | 15 Jun 2023 | | Form 8.5 (EPT/RI) - Shield Therapeutics Plc |
| 15/06/23 | 07:00:04 | 15 Jun 2023 | | Acceptance Level Update |
| 14/06/23 | 12:00:01 | 14 Jun 2023 | | Form 8.5 (EPT/RI) - Shield Therapeutics Plc |
| 14/06/23 | 07:00:09 | 14 Jun 2023 | | Acceptance Level Update |
| 13/06/23 | 12:00:01 | 13 Jun 2023 | | Form 8.5 (EPT/RI) - Shield Therapeutics Plc |
| 13/06/23 | 07:00:05 | 13 Jun 2023 | | Acceptance Level Update |
| 12/06/23 | 12:00:02 | 12 Jun 2023 | | Form 8.5 (EPT/RI) - Shield Therapeutics Plc |
| 12/06/23 | 07:00:04 | 12 Jun 2023 | | Acceptance Level Update |
| 09/06/23 | 12:00:02 | 9 Jun 2023 | | Form 8.5 (EPT/RI) - Shield Therapeutics Plc |
| 09/06/23 | 07:00:04 | 9 Jun 2023 | | Acceptance Level Update |
| 08/06/23 | 12:31:21 | 8 Jun 2023 | | Form 8.3 - Shield Therapeutics PLC (amendment) |
| 08/06/23 | 12:00:03 | 8 Jun 2023 | | Form 8.5 (EPT/RI) - Shield Therapeutics Plc |
| 08/06/23 | 07:00:07 | 8 Jun 2023 | | Acceptance Level Update |
| 07/06/23 | 12:00:02 | 7 Jun 2023 | | Form 8.5 (EPT/RI) - Shield Therapeutics Plc |
| 06/06/23 | 12:00:01 | 6 Jun 2023 | | Form 8.5 (EPT/RI) - Shield Therapeutics Plc |
| 06/06/23 | 10:10:00 | 6 Jun 2023 | | Grant of share options to the CEO |
| 05/06/23 | 12:00:04 | 5 Jun 2023 | | Form 8.5 (EPT/RI) - Shield Therapeutics Plc |
| 02/06/23 | 12:00:01 | 2 Jun 2023 | | Form 8.5 (EPT/RI) - Shield Therapeutics Plc |
| 01/06/23 | 12:00:01 | 1 Jun 2023 | | Form 8.5 (EPT/RI) - Shield Therapeutics Plc |
| 01/06/23 | 11:00:01 | 1 Jun 2023 | | Holding(s) in Company |
| 01/06/23 | 10:55:01 | 1 Jun 2023 | | Holding(s) in Company |
